Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 years or older
• People diagnosed with a type of non-Hodgkin lymphoma called DLBCL (including high grade B cell lymphoma, follicular lymphoma grade 3B, or transformed follicular lymphoma) who have already received at least 2 different systemic treatments, including at least one treatment containing an anti-CD20 antibody (a specific type of cancer-targeting drug)
• People diagnosed with follicular lymphoma grade 1–3A who have already received at least 2 different systemic treatments, including at least one treatment containing an anti-CD20 antibody
• People who have at least one risk factor that may increase the chance of a side effect called cytokine release syndrome, such as: being aged 65 or older, having elevated LDH levels in blood tests, having a higher-than-normal white blood cell count before anti-CD20 treatment, having advanced-stage disease (Stage III or IV), having tumours of a certain combined size, having a heart condition that the study doctor believes could increase risk, having lymphoma in the bone marrow, or having lymphoma cells circulating in the blood
• People whose bone marrow is working well enough, as shown by blood test results meeting specific minimum levels for red blood cells, white blood cells, and platelets (confirm specific thresholds with trial site)
• People with a general health and activity level rated 0, 1, or 2 on a standard medical scale (meaning able to carry out daily activities, possibly with some limitations)
• People whose kidneys are functioning at an adequate level, as measured by a standard blood or urine test (confirm specific threshold with trial site)
• People whose liver is functioning at an adequate level, as measured by specific blood test results (confirm specific thresholds with trial site)
• People who are able to understand and willing to sign a written consent form (or whose legal guardian can do so)
• Women who could become pregnant must agree to use a highly effective form of contraception (with less than 1% failure rate per year) or remain abstinent during the treatment period — methods such as periodic abstinence or withdrawal are not accepted
• Men must agree to use a condom plus an additional highly effective contraceptive method, or remain abstinent, during the treatment period, and must not donate sperm during this time

Who may not be able to join:

• People with a specific type of lymphoma called primary mediastinal B cell lymphoma
• People whose lymphoma is currently active in the brain, spinal fluid, or the membranes surrounding the brain and spinal cord
• People who have previously had a severe allergic or life-threatening reaction to an anti-CD20 antibody treatment
• People who have an active infection (bacterial, viral, fungal, or other) requiring treatment within 2 weeks before the first study dose, including active COVID-19
• People with an ongoing or active hepatitis B, hepatitis C, or CMV infection that requires treatment or preventive medication (resolved infections are not excluded)
• People with a currently active cancer other than certain non-invasive skin cancers or early-stage localised cancers (a history of past cancer does not automatically exclude someone)
• People who are HIV positive
• People with serious uncontrolled health conditions, including severe heart failure, unstable chest pain, uncontrolled irregular heartbeat, significant lung problems, or serious mental health or social circumstances that may make it difficult to follow the study requirements
• Women who are pregnant or breastfeeding (breastfeeding should not be restarted for at least 3 months after the last dose of the study drug)
• People with an active and clinically significant brain or neurological condition, such as uncontrolled epilepsy, seizures, severe brain injury, dementia, Parkinson's disease, or significant difficulty with movement or speech
• People who are expected to receive a specific chemotherapy combination (GemOx) and who have nerve damage in their hands or feet rated above a mild level at the time of joining the trial

Important: Always verify eligibility with the trial site directly before applying.